Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.
Kyverna Therapeutics Price Performance
Shares of NASDAQ KYTX traded up $0.11 during midday trading on Friday, reaching $2.38. 335,518 shares of the company's stock traded hands, compared to its average volume of 436,452. Kyverna Therapeutics has a one year low of $2.21 and a one year high of $28.05. The stock's 50 day simple moving average is $2.97 and its 200-day simple moving average is $4.38.
Hedge Funds Weigh In On Kyverna Therapeutics
A hedge fund recently raised its stake in Kyverna Therapeutics stock. Bank of America Corp DE increased its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 41.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,788 shares of the company's stock after acquiring an additional 6,400 shares during the quarter. Bank of America Corp DE owned about 0.05% of Kyverna Therapeutics worth $81,000 as of its most recent SEC filing. 18.08% of the stock is owned by institutional investors and hedge funds.
Kyverna Therapeutics Company Profile
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Further Reading
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
